Literature DB >> 2285495

Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide.

S Y Kim1, N L Benowitz.   

Abstract

Quinidine, procainamide and disopyramide are antiarrhythmic drugs in the class 1A category. These drugs have a low toxic to therapeutic ratio, and their use is associated with a number of serious adverse effects during long term therapy and life-threatening sequelae following acute overdose. Class 1A agents inhibit the fast inward sodium current and decrease the maximum rate of rise and amplitude of the cardiac action potential. Prolonged Q-T interval and, to a lesser extent, QRS duration may be observed at therapeutic concentrations of quinidine. With increasing plasma concentrations, progressive depression of automaticity and conduction velocity occur. 'Quinidine syncope' (a transient loss of consciousness due to paroxysmal ventricular tachycardia, frequently of the torsade de pointes type) occurs with therapeutic dosing, often in the first few days of therapy. Extracardiac adverse effects of quinidine include potentially intolerable gastrointestinal effects and hypersensitivity reactions such as fever, rash, blood dyscrasias and hepatitis. Procainamide produces electrophysiological changes that are similar to those of quinidine, although Q-T interval prolongation with the former is less pronounced at therapeutic concentrations. Hypersensitivity reactions including fever, rash and (more seriously) agranulocytosis are associated with procainamide, and a frequent adverse effect requiring cessation of therapy is the development of systemic lupus erythematosus. Of the 3 drugs, disopyramide has the most pronounced negative inotropic effects, which are especially significant in patients with pre-existing left ventricular dysfunction. As with quinidine, unexpected 'disopyramide syncope' at therapeutic concentrations has been described. Anticholinergic side effects are common with this drug and may require cessation of therapy. Disopyramide therapy may unpredictably induce severe hypoglycaemia. Severe intoxication with the class 1A agents may result from acute accidental or intentional overdose, or from accumulation of the drugs during long term therapy. Acute overdose can result in severe disturbances of cardiac conduction and hypotension, frequently accompanied by central nervous system toxicity. Decreased renal function can cause significant accumulation of procainamide and its active metabolite acecainide (N-acetyl-procainamide), resulting in severe intoxication. Mild to moderate renal dysfunction is less likely to lead to quinidine or disopyramide intoxication, unless renal failure is severe or concurrent hepatic dysfunction is present. Management of acute intoxication with class 1A drugs includes gut decontamination with provision of respiratory support and treatment of seizures as needed. Hypertonic sodium bicarbonate, by antagonising the inhibitory effect of quinidine on sodium conductance, may reverse many or all manifestations of cardiovascular toxicity.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2285495     DOI: 10.2165/00002018-199005060-00002

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  189 in total

1.  Quinidine therapy of chronic auricular fibrillation. The occurrence and mechanism of syncope.

Authors:  R ROKSETH; O STORSTEIN
Journal:  Arch Intern Med       Date:  1963-02

2.  Gastrointestinal dialysis of disopyramide in healthy subjects.

Authors:  K Arimori; H Kawano; M Nakano
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1989-06

3.  Respiratory failure produced by severe procainamide intoxication in a patient with preexisting peripheral neuropathy caused by amiodarone.

Authors:  B Miller; A Skupin; M Rubenfire; O Bigman
Journal:  Chest       Date:  1988-09       Impact factor: 9.410

4.  The noninterference of aluminum hydroxide gel with quinidine sulfate absorption: an approach to control quinidine-induced diarrhea.

Authors:  J A Romankiewicz; M Reidenberg; D Drayer; J E Franklin
Journal:  Am Heart J       Date:  1978-10       Impact factor: 4.749

5.  Acute intoxication with diisopyramide: clinical and experimental study by hemoperfusion an Amberlite XAD 4 resin.

Authors:  B Gosselin; D Mathieu; C Chopin; F Wattel; B Dupuis; J M Haguenoer; M Desprez
Journal:  Clin Toxicol       Date:  1980-10       Impact factor: 4.467

6.  Torsade de pointes due to quinidine: observations in 31 patients.

Authors:  J L Bauman; R A Bauernfeind; J V Hoff; B Strasberg; S Swiryn; K M Rosen
Journal:  Am Heart J       Date:  1984-03       Impact factor: 4.749

7.  Agranulocytosis secondary to extended-release procainamide: a case report and review of the literature. A case of agranulocytosis caused by procainamide in a patient who had undergone open-heart surgery.

Authors:  P B Malters; A G Salem
Journal:  S D J Med       Date:  1987-02

8.  Effects of intravenous disopyramide and quinidine on normal myocardium and on the characteristics of arrhythmias: intraindividual comparison in patients with sustained ventricular tachycardia.

Authors:  I Rizos; J Brachmann; W Lengfelder; C Schmitt; K von Olshausen; W Kübler; J Senges
Journal:  Eur Heart J       Date:  1987-02       Impact factor: 29.983

9.  Serologic changes during induction of lupus-like disease by procainamide.

Authors:  R L Rubin; S R Nusinow; A D Johnson; D S Rubenson; J G Curd; E M Tan
Journal:  Am J Med       Date:  1986-05       Impact factor: 4.965

10.  Association of antibody to histone complex H2A-H2B with symptomatic procainamide-induced lupus.

Authors:  M C Totoritis; E M Tan; E M McNally; R L Rubin
Journal:  N Engl J Med       Date:  1988-06-02       Impact factor: 91.245

View more
  9 in total

1.  A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes.

Authors:  C L Lawrence; M H Bridgland-Taylor; C E Pollard; T G Hammond; J-P Valentin
Journal:  Br J Pharmacol       Date:  2006-10-09       Impact factor: 8.739

Review 2.  Drug-related lupus. Incidence, mechanisms and clinical implications.

Authors:  L E Adams; E V Hess
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

3.  New potential antimalarial agents: therapeutic-index evaluation of pyrroloquinazolinediamine and its prodrugs in a rat model of severe malaria.

Authors:  Lisa H Xie; Qigui Li; Ai J Lin; Kirsten Smith; Jing Zhang; Donald S Skillman
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

4.  State-dependent blockade of human ether-a-go-go-related gene (hERG) K(+) channels by changrolin in stably transfected HEK293 cells.

Authors:  Wei-hai Chen; Wen-yi Wang; Jie Zhang; Ding Yang; Yi-ping Wang
Journal:  Acta Pharmacol Sin       Date:  2010-08       Impact factor: 6.150

5.  Inhibition of the ATP-sensitive potassium channel by class I antiarrhythmic agent, cibenzoline, in rat pancreatic beta-cells.

Authors:  M Kakei; M Nakazaki; T Kamisaki; I Nagayama; Y Fukamachi; H Tanaka
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

6.  Role of late sodium current in modulating the proarrhythmic and antiarrhythmic effects of quinidine.

Authors:  Lin Wu; Donglin Guo; Hong Li; James Hackett; Gan-Xin Yan; Zhen Jiao; Charles Antzelevitch; John C Shryock; Luiz Belardinelli
Journal:  Heart Rhythm       Date:  2008-09-06       Impact factor: 6.343

7.  Frequency of laboratory monitoring of chronic medications administered to nursing facility residents: results of a national Internet-based study.

Authors:  Steven M Handler; Brian H Shirts; Subashan Perera; Michael J Becich; Nicholas G Castle; Joseph T Hanlon
Journal:  Consult Pharm       Date:  2008-05

Review 8.  Drug-induced cardiac arrhythmias: incidence, prevention and management.

Authors:  J C Doig
Journal:  Drug Saf       Date:  1997-10       Impact factor: 5.228

9.  Optogenetic manipulation of cardiac electrical dynamics using sub-threshold illumination: dissecting the role of cardiac alternans in terminating rapid rhythms.

Authors:  V Biasci; L Santini; G A Marchal; S Hussaini; C Ferrantini; R Coppini; L M Loew; S Luther; M Campione; C Poggesi; F S Pavone; E Cerbai; G Bub; L Sacconi
Journal:  Basic Res Cardiol       Date:  2022-04-29       Impact factor: 12.416

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.